<DOC>
	<DOCNO>NCT02494986</DOCNO>
	<brief_summary>The purpose study provide continue access rilpivirine ( RPV ) participant treat RPV clinical development pediatric study rilpivirine , time roll-over , experience expect continue experience clinical benefit RPV treatment .</brief_summary>
	<brief_title>A Roll-over Study With Rilpivirine Human Immunodeficiency Virus Type 1 ( HIV-1 ) Infected Participants Who Participated Rilpivirine Pediatric Studies</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter ( 1 hospital medical school team work study ) , roll-over study provide continue access RPV human immunodeficiency virus type 1 ( HIV-1 ) infect participant . All enrol participant continue receive RPV combination investigator-selected background regimen consist 2 nucleoside/nucleotide reverse transcriptase inhibitor ( N [ ] RTIs ) . Participants continue receive RPV study longer benefit RPV treatment , meet least 1 withdrawal criterion , RPV license adult/pediatric use ( depend age participant ) and/or available/accessible outside clinical study setting , whichever come first .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Participants ( legally acceptable representative ) must sign Informed Consent Form ( ICF ) indicate understand purpose procedure require study willing participate study . Assent also require child capable understanding nature study ( typically 7 year age old ) Participants must human immunodeficiency virus type 1 ( HIV1 ) infect must previously treat rilpivirine ( RPV ) 25 mg qd ( weightadjusted dose ) clinical development pediatric study complete protocol define treatment period Participants must benefit treatment RPV , accord efficacy safety criterion set protocol pediatric study RPV participant participate prior rollover study , must expect continue benefit treatment opinion investigator Participants must able willing comply current protocol requirement Participants general medical condition , opinion investigator , interfere participation study Participants use disallowed concomitant treatment Pregnant participant Female participant childbearing potential nonvasectomized heterosexually active male participant willing continue practice birth control method study great equal ( â‰¥ ) 1 month end study ( last intake RPV ) Participants withdrawn pediatric study RPV participate prior rollover study , base mandatory withdrawal criterion</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Human immunodeficiency virus type 1</keyword>
	<keyword>Rilpivirine</keyword>
	<keyword>Roll-over study</keyword>
</DOC>